Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
This study has been terminated.
(Two patients in the first dose level be counted as reaching DLT. DSMB recommend terminated early this trial.)
Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
National Cheng-Kung University Hospital
Chang Gung Memorial Hospital
Information provided by:
National Health Research Institutes, Taiwan
ClinicalTrials.gov Identifier:
NCT00971126
First received: July 1, 2009
Last updated: July 20, 2011
Last verified: September 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Estimated Study Completion Date: | December 2011 |
| Estimated Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |